- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00458302
Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir (MONET)
A Randomised, Controlled, Open-label Trial to Compare the Efficacy, Safety and Tolerability of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg O.D. vs a Triple Combination Therapy With DRV/r in HIV-1 Infected Patients With Undetectable Plasma HIV-RNA on Their Current Treatments.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is randomised (patients are assigned different treatments based on chance), controlled, open-label trial to compare the efficacy, safety and tolerability of darunavir/ritonavir (DRV/r) 800/100 mg once a day (O.D.) as a monotherapy versus a triple combination therapy containing 2 nucleosides and DRV/r in 250 HIV-1 infected patients. Patients will be considered eligible if they have not changed any antiretroviral drugs for at least 8 weeks prior to screening and have documented evidence of plasma viral load (or plasma HIV-1 RNA) < 50 copies/mL for at least 24 weeks prior to being screened. The trial will consist of a screening period up to 4 weeks, a 48-week treatment period, followed by a 4-week follow-up (FU) period. The primary objective is to demonstrate non-inferiority in efficacy of DRV/r versus the triple combination therapy containing DRV/r, with respect to confirmed virologic response, defined as plasma HIV-1 RNA < 50 copies/mL at 48 weeks.Patients will be assigned a study medication based on a 1:1 ratio to either switch to a triple combination therapy containing 2 nucleosides and DRV/r 800/100 mg O.D, or initiate monotherapy with DRV/r 800/100 mg O.D. Patients in the triple combination arm who are already on 2 nucleosides prior to randomisation may remain on these or switch them at baseline. Patients randomised to the monotherapy arm will discontinue Highly Active Antiretroviral Therapy (HAART) at baseline and commence DRV/r 800/100 mg O.D. A Data and Safety Monitoring Board (DSMB) has been commissioned for this study. The role of the DSMB is to review the progress of the trial and the accumulating data to detect evidence of early safety issues for the patients while the trial is ongoing. An interim analysis will be performed after 24 weeks of treatment. The results of the Week 24 analysis will be used to determine whether long-term follow-up to 72 and 96 weeks will be done. The protease inhibitor (PI) component of the regimen cannot be changed until the end of the treatment period and the nucleoside reverse transcriptase inhibitors (NRTIs) cannot be modified until the end of the treatment period with the following exception: single antiretroviral (ARV) substitutions will be allowed for tolerability/toxicity reasons, as long as this can be linked to an adverse event (AE) or an serious adverse event (SAE). After withdrawal of the patient from the trial, changes in the ARV regimen are allowed after the assessments of the withdrawal visit have been performed.
Temporary interruption of all ARVs will be allowed in the event of suspected toxicity, as long as the temporary interruption is associated with and can be linked to an AE or a SAE. For the control arm, the nucleoside analogues could be re-optimized at baseline or on study, and all approved ARVs allowed. However, PIs other than DRV/r are not allowed during the treatment period. Patients who cannot resume study medication will have to be withdrawn. A physical examination will be done at protocol-scheduled visits and vital signs will be monitored at each study visit. In addition, at each study visit, every patient will be asked about the occurrence of or change to AEs since they were last seen by the investigator. Laboratory samples for haematology and serum chemistry will be drawn and the results determined and transmitted to the investigator. Urinalysis will be performed. Pregnancy test will be done at each visit for female participants of child-bearing potential. The primary endpoint will be the proportion with virologic response, defined as a confirmed plasma HIV-1 RNA < 50 copies/mL at Week 48.The study hypothesis is that DRV/r monotherapy will be as effective as a triple combination regimen and will be well tolerated in this early pre-treated HIV-1 patients. Two 400mg tablets of darunavir once daily orally within 30 minutes after completion of a meal for 48 weeks.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Wien, Austria
-
-
-
-
-
Antwerpen, Belgium
-
Bruxelles, Belgium
-
-
-
-
-
Aarhus, Denmark
-
Copenhagen, Denmark
-
Hvidovre, Denmark
-
Odense, Denmark
-
-
-
-
-
Berlin, Germany
-
Frankfurt, Germany
-
Hamburg, Germany
-
Hannover, Germany
-
Kÿln N/A, Germany
-
-
-
-
-
Budapest, Hungary
-
-
-
-
-
Jerusalem, Israel
-
Tel Aviv, Israel
-
Tel Hashomer, Israel
-
-
-
-
-
Lisbon, Portugal
-
Porto, Portugal
-
-
-
-
-
Moscow, Russian Federation
-
Saint-Petersburg, Russian Federation
-
-
-
-
-
Barcelona, Spain
-
Barcelona N/A, Spain
-
Donostia Guipuzcoa, Spain
-
Granada, Spain
-
Madrid, Spain
-
Valladolid N/A, Spain
-
-
-
-
-
St Gallen, Switzerland
-
-
-
-
-
London, United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with documented HIV-1 infection
- Patients currently receiving HAART for at least 24 weeks
- Plasma viral load < 50 copies/mL for at least 24 weeks prior to screening (two results must be documented)
- Patients taking the same antiretroviral combination for at least 8 weeks before screening
- Patients and physician's preference to change the current HAART regimen for reasons of simplification and/or toxicity
- CD4 > 100/mm3 at the start of HAART and > 200/mm3 at screening.
Exclusion Criteria:
- No history of virological failure defined as two consecutive plasma HIV-1 RNA > 500 copies/mL while on previous or current antiretroviral therapy
- No history of any primary PI mutations as defined by the IAS-USA guidelines 2006
- No patients co-infected with hepatitis B
- No pregnant or breastfeeding women
- No active clinically significant disease or life threatening disease or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: darunavir monotherapy
darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
|
800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
|
EXPERIMENTAL: darunavir + 2 NRTI
darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
|
800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virological Response [Per Protocol (PP) - Time to Loss of Virologic Response (TLOVR), < 50 Copies/ml, Week 48]
Time Frame: Week 48
|
Virological response is defined as the number of patients in the PP population with a plasma viral load < 50 HIV RNA copies/ml at Week 48.
Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR).
In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure* (referred to as a Switch Equals Failure analysis).
*Discontinuations and rechallenge with NRTIs are taken into account until Week 48
|
Week 48
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Virological Response [Intent To Treat (ITT) - TLOVR, < 50 Copies/ml, Week 48]
Time Frame: Week 48
|
Virological response is defined as the number of patients in the ITT population with a plasma viral load < 50 HIV RNA copies/ml at Week 48.
Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR).
In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure* (referred to as a Switch Equals Failure analysis).
*Discontinuations and rechallenge with NRTIs are taken into account until start of Week 48 window
|
Week 48
|
Virological Response [Per Protocol (PP), TLOVR - Switch Equals Failure, < 50 Copies/ml, Week 144]
Time Frame: Week 144
|
Virological response is defined as the number of patients in the PP population with a plasma viral load < 50 HIV RNA copies/ml at Week 144.
Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR).
In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure* (referred to as a Switch Equals Failure analysis).
*Discontinuations and rechallenge with NRTIs are taken into account until Week 144
|
Week 144
|
Virological Response [Intent To Treat (ITT), TLOVR - All Switches Included, < 50 Copies/ml, Week 144]
Time Frame: Week 144
|
Virological response is defined as the number of patients in the ITT population with a plasma viral load < 50 HIV RNA copies/ml at Week 144.
Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR).
All switches included means that all data even after any changes of treatment were kept.
*Discontinuations and rechallenge with NRTIs are taken into account until start of Week 144 window.
|
Week 144
|
Virological Response [Per Protocol (PP), TLOVR - Switch Equals Failure, <200 Copies/ml, Week 144]
Time Frame: week 144
|
Virological response is defined as the number of patients in the PP population with a plasma viral load < 200 HIV RNA copies/ml at Week 144.
Treatment failure was defined as two consecutive HIV RNA levels ≥ 50 copies/mL, or discontinuation of randomised treatment (known as TLOVR).
In addition, any switch in background nucleoside reverse transcriptase inhibitors (NRTIs) equaled failure* (referred to as a Switch Equals Failure analysis).
*Discontinuations and rechallenge with NRTIs are taken into account until Week 144
|
week 144
|
Mean Change From Baseline in CD4+ Cell Count
Time Frame: at week 4, 12, 24, 36, 48, 60, 72, 84, 96, 112, 128, 144
|
The mean change in CD4+ cell count from baseline was calculated with a last observation carried forward method; i.e. the last observed value was carried forward, irrespective of the reason for discontinuation.
|
at week 4, 12, 24, 36, 48, 60, 72, 84, 96, 112, 128, 144
|
Resistance Determinations
Time Frame: at each visit from baseline to week 144
|
Number of patients with resistance mutations at any time point when a patient had a viral load > 50 copies/mL after randomization.
|
at each visit from baseline to week 144
|
Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Total Score
Time Frame: at baseline, week 48, 96 and 144
|
The FAHI is a validated health-related quality of life questionnaire.
The questionnaire consist of 44 items and includes 5 functional scales (physical, social, emotional, functional and global well-being and cognitive function).
Each item is assessing the impact of HIV on a scale from 0 (not at all) to 5 (very much).
|
at baseline, week 48, 96 and 144
|
Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Cognitive Function Subscale
Time Frame: at baseline, week 48, 96 and 144
|
The FAHI cognitive function subscale.
Each item is assessing the impact of HIV on cognitive function on a scale from 0 (not at all) to 5 (very much).
|
at baseline, week 48, 96 and 144
|
Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Emotional Well-Being Subscale
Time Frame: at baseline, week 48, 96 and 144
|
The FAHI emotional well-being subscale.
Each item is assessing the impact of HIV on emotional well-being on a scale from 0 (not at all) to 5 (very much).
|
at baseline, week 48, 96 and 144
|
Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Functional and Global Well-Being Subscale
Time Frame: at baseline, week 48, 96 and 144
|
The FAHI functional and global well-being subscale.
Each item is assessing the impact of HIV on functional and global well-being on a scale from 0 (not at all) to 5 (very much).
|
at baseline, week 48, 96 and 144
|
Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Physical Well-Being Subscale
Time Frame: at baseline, week 48, 96 and 144
|
The FAHI physical well-being subscale.
Each item is assessing the impact of HIV on physical well-being on a scale from 0 (not at all) to 5 (very much).
|
at baseline, week 48, 96 and 144
|
Change From Baseline in Health-Related Quality of Life - FAHI Questionnaire Social Well-Being Subscale
Time Frame: at baseline, week 48, 96 and 144
|
The FAHI social well-being subscale.
Each item is assessing the impact of HIV on physical well-being on a scale from 0 (not at all) to 5 (very much).
|
at baseline, week 48, 96 and 144
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immune System Diseases
- Slow Virus Diseases
- HIV Infections
- Acquired Immunodeficiency Syndrome
- Immunologic Deficiency Syndromes
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Darunavir
Other Study ID Numbers
- CR013159
- TMC114HIV3006 (OTHER: Janssen-Cilag International NV)
- 2006-006437-40 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on darunavir (DRV, TMC114)
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompletedHuman Immunodeficiency Virus (HIV)United States, Spain, South Africa
-
Tibotec Pharmaceuticals, IrelandCompletedHuman Immunodeficiency Virus - Type 1United States, France, United Kingdom, Germany, Taiwan, Spain, Argentina, Chile, Malaysia, Panama, Romania, South Africa, Thailand, Brazil, Puerto Rico, Austria, Hungary, Australia, Guatemala
-
Gilead SciencesJanssen Research & Development, LLCCompletedHIV Infections | Acquired Immunodeficiency SyndromeUnited States, Puerto Rico
-
Community Research Initiative of New EnglandCompletedHIV InfectionsUnited States
-
Janssen Research & Development, LLCCompleted
-
Janssen Pharmaceutical K.K.Completed
-
Tibotec Pharmaceuticals, IrelandTerminated
-
ASST Fatebenefratelli SaccoElisa Colella, M.D.; Valentina Di Cristo, M.D.; Massimo Galli, M.D.Completed